This page shows the latest bladder cancer news and features for those working in and with pharma, biotech and healthcare.
An estimated 26, 500 people in the US will be diagnosed with gastric cancer in 2023. ... Beyond gastric cancer, Keytruda holds approvals to treat a wide variety of cancers, including specific cases of bladder cancer, melanoma and Hodgkin’s lymphoma.
of disease across multiple types of cancer, we hope to reduce disease recurrence and ultimately improve overall survival outcomes. ... Beyond RCC, Keytruda holds approvals to treat a wide variety of cancers, including specific cases of bladder cancer,
Beyond BTC, Keytruda holds approvals to treat a wide variety of cancers, including specific cases of bladder cancer, melanoma and Hodgkin’s lymphoma. ... Last month, the therapy was approved in the US as part of a combination treatment for patients
The approval marks the sixth non-small cell lung cancer indication for the anti-PD-1 therapy. ... Beyond lung cancer, Keytruda holds approvals to treat a wide variety of cancers, including specific cases of bladder cancer, melanoma and Hodgkin’s
Over 82, 000 people in the US will be be diagnosed with bladder cancer in 2023. ... The therapy already holds approvals to treat a wide variety of cancers, including specific cases of locally advanced or metastatic urothelial carcinoma and
At the time of the announcement, Pfizer's oncology portfolio included 24 approved drugs, while Seagen's included Adcetris for lymphomas, Padcev for bladder cancers, Tivdak for cervical cancer, and Tukysa ... the deal could reduce competition in the
More from news
Approximately 34 fully matching, plus 135 partially matching documents found.
a later stage, where it is more likely that the cancer is less treatable. ... Unlike the female equivalent – breast cancer – there is no automatic screening for prostate cancer.
those living with urothelial carcinoma (UC), the most common type of bladder cancer. ... and metastatic bladder cancer harbouring an FGFR alteration, addressing the considerable unmet need for patients living with this disease.
This treatment quickly became the ‘gold standard’ for women with metastatic breast cancer. ... a terminal disease, and more towards helping cancer patients manage their condition effectively.
had transformative results in some diseases such as melanoma, non-small cell lung cancer and bladder cancer – among others. ... Cavatak is now in three trials in melanoma, bladder cancer and NSCLC that are due to generate results in 2018/2019.
Immunomic Therapeutics will retain the rights to its LAMP-vax platform for other applications, including cancer immunotherapy. ... MCNA for non-muscle invasive bladder cancer (BLA filed). Licence. 137. Proteros biostructures/ Merck &Co.
More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.
It’s the first major appointment for Ferring in 2019, and the company says Opdyke will lead the potential commercial launch of its investigational gene therapy for bladder cancer patients in ... He said: “At the heart of cancer immunity is a T cell
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
The objective for this congress is for HCPs to learn from physicians and scientists who present their research in prostate, bladder, and kidney cancer. ... highlighting the ground-breaking research in cancer care.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
No results were found
We’re a digital CX agency collaborating with healthcare and pharmaceutical organisations to help them connect more deeply with their audiences...